Berry Wealth Group LP Buys New Holdings in Amgen Inc. $AMGN

Amgen beat estimates in the latest quarter with EPS of $5.64 versus $5.01 consensus and revenue of $9.56B (vs. $8.98B), a 12.4% year-over-year revenue increase, and set FY2025 guidance of $20.600–21.400 EPS (market average 20.62). The company declared a $2.38 quarterly dividend (annualized $9.52, yield ~2.8%) while analysts lifted several price targets and institutional buyers (notably Vanguard, Norges Bank and large stake increases cited) expanded positions; insiders sold ~10,908 shares (~$3.67M) over the past 90 days. With market capitalization around $185.6B, a PE of 28.18 and raised analyst targets (consensus price $333.74), the fundamental/earnings beat and dividend support a constructive view, though elevated payout ratio (73.57%) and insider selling merit monitoring.

Analysis

Market structure: Large institutional buys (Vanguard, Norges, Nuveen) plus a beat-and-raise create near-term demand pressure that supports price above the 50-day SMA (~$307) and near-term resistance at the 52-week high ~$346. Direct winners are existing AMGN equity holders and active call sellers; losers include cash bondholders if leverage-driven equity volatility spikes (debt/equity = 7.24). Expect modest pricing power preservation in mature biologics but margin upside largely limited to productivity and specialty launches, not pricing shocks.

Risk assessment: Key tail risks are adverse pivotal trial readouts, biosimilar market share erosion for Enbrel/Repatha, or a policy-driven US price reset—any one could compress EPS vs. FY25 guidance (20.6–21.4) and trigger >15% drawdown. Immediate (days) reaction will be driven by FMV flows and options gamma; short-term (weeks/months) hinges on guidance execution and Qs; long-term (quarters/years) depends on pipeline readouts and ability to delever given high payout ratio (~74%). Hidden dependency: ROE (174%) appears inflated by buybacks/leverage — a liquidity strain or dividend cut risk if FCF weakens.

Trade implications: Given consensus PT ~$334 vs. spot ~$345, risk/reward is asymmetric absent a clear catalyst. Tactical plays: buy on pullbacks to $320–300 (50–200 DMA), or collect premium via put-selling (strike $320–$300) with margin to own. Hedge with downside protection (buy 6–12 month puts) if initiating new exposure; consider credit-spread income if volatility remains low.

Contrarian angle: The market is underpricing leverage and dividend vulnerability; insiders selling (~10.9k shares recently) plus high payout ratio suggest downside if earnings slip. Conversely, consensus may be underestimating Enbrel/Otezla/Prolia tail revenues and cost synergies — a successful pipeline readout could re-rate the stock above $380. Historical parallel: large-cap biotechs often gap up post-earnings then mean-revert if no follow‑on catalysts; position size and option structure must reflect catalyst calendar.

Key Decisions for Investors

• Establish a 2–3% long position in AMGN (ticker AMGN) on a pullback to $320; add up to 1% more if price falls to $300. Set a hard stop at $280 (approx -12.5% from $320 entry) and review after next quarterly report (~90 days).
• Sell cash-secured puts: sell AMGN Mar 2025 320 puts sized to acquire up to 3% position if assigned; collect premium and target net entry ≤ $310. Close or roll if premium-implied delta >0.35 or underlying >$340 before expiration.
• If bullish longer-term, buy 12‑18 month LEAP calls (e.g., Jan 2026 strike 360) sized to 1% notional as a low-cash convexity bet; hedge by buying a protective 9–12 month put (strike 300) if >2% portfolio allocation.
• Pair trade: long AMGN (1.5%) vs short XLV (0.75%) or PFE (0.75%) to express relative outperformance view — reweight if AMGN/Treasury spreads or debt metrics worsen. Target 3–6 month horizon and trim if AMGN underperforms XLV by >6%.
• Monitor within 30 days: (1) any guidance update vs FY25 midpoint 21.0 EPS, (2) debt/EBITDA or net leverage moves and dividend declarations (dividend sustainability if payout ratio >75%), and (3) upcoming pivotal readouts; reduce exposure by 50% if guidance trimmed by >3% or if debt covenants are signaled.